Whipple’s disease (WD) is a rare disease that predominantly affects middle-aged white men, and its diagnosis is often delayed because it is misdiagnosed as rheumatoid arthritis. A new study in Orphanet Journal of Rare Diseases aimed to describe clinical symptoms of WD and appropriate treatment.
Whipple’s disease (WD) is a rare disease that predominantly affects middle-aged white men, and its diagnosis is often delayed because it is misdiagnosed as rheumatoid arthritis (RA). A new study in Orphanet Journal of Rare Diseases aimed to describe clinical symptoms of WD and appropriate treatment.
Researchers identified 7 patients who had been misdiagnosed with RA. The median time from onset of symptoms to the diagnosis of WD was 5 years. During that time, all but 1 patient received immunosuppressive treatment. However, WD is a chronic infectious disorder caused by Tropheryma whipplei (TW) and should be treated with antibiotics.
“Without antibiotic treatment the natural course of WD may be fatal; erroneously induced immunosuppressive treatment may even accelerate the clinical progression of the disease,” the authors wrote.
Following the diagnosis of WD, all patients were initiated on antibiotic treatment.
The researchers determined that the diagnosis of RA was likely made because the patients “suffered from joint manifestations mimicking seronegative RA,” plus the course of the disease involved the small joints in all patients and joint erosions in 3 of the patients. Joint manifestations of WD infrequently involve the small joints.
“The fact that bone erosions of the small joints are rather characteristic for RA and are part of the 1987 ACR-classification criteria for RA might have led to the wrong diagnosis in the reported patients,” the authors wrote.
Establishing a diagnosis of WD requires TW-polymerase chain reaction testing of synovial fluid to distinguish the infection from RA, and the authors recommend reevaluating seronegative RA patients with prolonged disease course and insufficient treatment response.
“… it is possible that destructive arthritis is misinterpreted even by radiologists and that a wrong interpretation of radiographs may lead to the wrong diagnoses,” the authors wrote. “Thus, both rheumatologists and radiologists should increase their awareness for rare diseases like WD as a reason for erosive bone changes.”
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More